STUDY DESIGN AND METHODS:
The propositus and the parents from a case of suspected neonatal alloimmune thrombocytopenia (NAIT) were investigated using serologic and molecular techniques to detect and identify relevant platelet-specific antibodies and for HPA typing. Calculations of molecular dynamics were undertaken to explore potential variations in the molecular structure.
RESULTS:
Maternal antibodies were detected that were reactive only in crossmatch with paternal platelets using the platelet immunofluorescence test (PIFT) and a GPIIb/IIIa monoclonal antibody immobilization of platelet antigen (MAIPA) assay. In the propositus and father, a novel mutation c.1373 A > G was found in exon 10 of ITGB3 resulting in the substitution of an aspartic acid for a glycine (p.Asp458Gly). Recombinant GPIIIa glycoprotein mutated to contain the novel mutation and expressed in HEK293 cells with GPIIb was also specifically recognized by maternal antibodies. Calculations of molecular dynamics identified that the mutation was in a structurally constrained site.
CONCLUSION:
This case describes a low-frequency platelet antigen (Asp458Gly) that defines a further alloantigenic target in NAIT. The case emphasizes the role of the platelet crossmatch as the single most useful tool to establish evidence of immunization of lowfrequency platelet glycoprotein polymorphisms. A crossmatch should always be performed where there is strong clinical evidence of NAIT but initial laboratory investigations are not confirmatory.
T he placental transfer of platelet-specific antibodies results in neonatal alloimmune thrombocytopenia (NAIT) with a spectrum of clinical sequelae ranging from mild thrombocytopenia through to intrauterine growth retardation, intracranial hemorrhage, and fetal loss. [1] [2] [3] In the white population, NAIT is predominantly caused either by HPA-1a (70-80% of cases) or HPA-5b specific antibodies (10-15% of cases) with an overall incidence reported between 1 in 800 and 1 in 1000 live births. [1] [2] [3] The causative alloantibodies are produced as a result of maternal immunization against fetal human platelet antigens (HPAs) inherited from the father but are absent in the mother. Of the currently 29 HPA antigens, 28 arise from single amino acid substitutions on one of four different glycoproteins. [4] [5] [6] The amino acid substitutions are predominantly encoded by single nucleotide polymorphisms (SNPs); the only exception is HPA-14bw, defined by a triplet deletion rather than a SNP. The GPIIb/IIIa heterodimeric integrin (also known as αIIb/β3) is the most abundant and biologically significant protein on the platelet surface. The GPIIb glycoprotein (αIIb) is encoded by the ITGA2B gene, and the GPIIIa glycoprotein (β3) is encoded by the ITGB3 gene. Most (19) of the HPA SNPs occur within the coding region of ITGB3. [4] [5] [6] Lowfrequency HPAs are identified in NAIT cases by the presence of maternal platelet antibodies reactive only with paternal platelets rather than by screening against HPAtyped panel cells. The clinical relevance of low-frequency HPAs in NAIT is well recognized, [8] [9] [10] [11] and this report describes a further example of a low-frequency antigen associated with ITGB3.
CASE REPORT
A healthy white 32-year-old mother Bl(a) had a normal vaginal delivery at 40 weeks. The infant presented with severe thrombocytopenia (platelet count of 2 × 10 9 /L that was confirmed on repeat sampling) and petechiae on Day (D) 0 of life, but other hematologic indices were normal. The maternal platelet count was within the normal range. On D + 1, following transfusion of HPA-1a(−)5b(−) apheresis platelets, the infant's platelet count had increased to 159 × 10 9 /L. Over the next 6 days, the platelet count gradually decreased to 29 × 10 9 /L. At this stage, standard platelet immunology investigations for NAIT had excluded immunization against HPA-1a or -5b and, on D + 7, a further neonatal apheresis platelet unit was transfused from a donor who was not HPA1a(−)5b(−). The platelet count increased to 129 × 
MATERIALS AND METHODS

Sera and antibodies
Monoclonal antibodies (MoAbs) against GPIIb/IIIa (clones PAB1 & PAB6), GPIb/IX/V (PAB5), GPIa/IIa (P16), GPV (SW16), and HLA (W6/32) were provided by the International Blood Group Reference Laboratory. Commercial MoAbs specific for human GPIIb (CD41) were obtained from Becton Dickinson. MoAbs specific for CD109 (TEA2/16) were purchased from DAKO. HPA-1a, -3a, and -5b specific antisera prepared as sensitivity controls were purchased from the National Institute for Biological Standards and Control. Additional HPA-specific antisera were obtained from previously confirmed cases of neonatal alloimmune thrombocytopenia (FNAIT). HLA class I specific antisera were obtained from alloimmunized plateletrefractory patients, identified by Luminex and designated HLA-1. Sera without detectable HPA or HLA class I specific antibodies (AB44) was obtained from a nontransfused blood group AB male volunteer blood donor.
Serologic studies
Maternal serum was initially investigated using a platelet immunofluorescence test (PIFT) 12 
HPA genotyping
Genomic DNA was isolated from whole blood using MagNA Pure nucleic acid isolation kits on a Roche MagNA Pure Compact instrument (Roche Diagnostics).
Genotyping for HPA-1 to -5, -6w, -9w, and HPA-15 was initially performed using an in-house polymerase chain reaction (PCR) with sequence-based typing (PCR-SBT) method as previously described. 4 Primer sequences and amplification conditions are available upon request. Additional HPA genotyping for HPA-1 to -11 and -15 was performed using a BLOOD chipID assay (Progenika Biopharma).
DNA sequencing of ITGA2B and ITGB3 exons
Amplification of the ITGA2B and ITGB3 exons was performed as previously described. 5 Direct sequencing of the PCR products was performed in both directions for each gene using both sense and antisense primers that had been used to produce the initial PCR amplicon. PCR products were purified using AMPure beads (Beckman Coulter UK) followed by application of Big Dye Terminator v.1.1 (Applied Biosystems) chemistry. Data were collected on an ABI3130xl genetic analyzer using foundation data collection software v.3.0 and then analyzed using Seqscape v.2.6 software (Applied Biosystems) and Mutation Surveyor software v.5.0.1 (SoftGenetics). Genotyping of 100 blood donor DNA samples for the "Bl(a)" mutation was performed by PCR-SBT as outlined earlier using primers that were specific for exon 10 on ITGB3.
Next-generation sequencing
Indexed DNA libraries were prepared from 50 ng genomic DNA obtained from the infant and mother using a customdesigned HaloPlex high-sensitivity target-enrichment assay (Agilent Technologies) following the manufacturer's instructions. All HPA coding exons plus 50 nucleotides of the respective 5 0 and 3 0 flanking intronic regions of the ITGB3
and ITGA2B genes were targeted. 15 Pooled DNA libraries were sequenced on a MiSeq (Illumina) using 2 × 151 paired-end chemistry, with MiSeq reporter settings adjusted to generate FASTQ files for index reads. FASTQ files were subsequently analyzed using SureCall NGS data analysis software v.3.0.3.1 (Agilent Technologies), applying the HaloPlex default for pair analysis (Tumor Normal Method) with the maternal sample used as the reference sequence. Nucleotide differences between infant and mother were inspected for discrepancies.
Additional sera and monoclonal antibodies for recombinant protein expression
Three separate serum samples were obtained from the mother at D + 1, D + 7, and D + 90 and were designated Anti-Bl(a) D + 1 to Bl(a) D + 90, respectively. Control sera (designated C1, C2, and C3) were from untransfused blood group AB male donors.
Murine monoclonal antibodies against CD41 (clone PM6/248) and CD61 (clone PM6/13) were purchased from AbD Serotec and used for flow cytometry as recommended by the manufacturer. Isotype control immunoglobulin (Ig)G was from DAKO. Secondary goat-antihuman IgG red phycoerythrin (RPE)-coupled antibody was from Jackson Immunoresearch; goat antimouse IgG and RPE-coupled antibody was purchased from DAKO.
DNA constructs and transfection
DNA constructs and transfected HEK293 cells were prepared according to the methodology previously described. 5 Briefly, cDNA encoding platelet GPIIb (National Center for Biotechnology Information [NCBI] accession no. BC126442) or GPIIIa (accession no. BC127666) was amplified by PCR from existing clones 5 using specific primers and cloned into pEGFP N3 (GPIIb; Clontech) or pcDNA 3.1+ zeo (GPIIIa; Invitrogen) vectors. The mutation encoding glycine at amino acid position 458 in the mature GPIIIa protein (amino acid 484 in the propeptide) was introduced using a Quick Change Lightning Multi Kit (Agilent Technologies). The GPIIb construct was expressed with the green fluorescent protein (GFP) fusion tag to facilitate tracking of the expressed protein in the transfected cells. HEK293 cells (Health Protection Agency) were transfected with the constructs just described using TransIT 2020 transfection reagent (Mirus Bio) and used for flow cytometry analysis after 24 hours.
Flow cytometry of HEK293 cells
Transfected and untransfected wild-type control HEK293 cells were mechanically detached using a pipette, centrifuged at 600 × g for 1 minute and washed with phosphatebuffered saline (PBS) containing 0.5% (w/v) bovine serum albumin (BSA) (PBSB). For data analysis, the X-mean of RPE-labeled GFPexpressing cells was collected from at least three independent experiments and averaged. Statistical analysis was performed with Microsoft Excel to calculate p values for each set of data in a t test.
Molecular dynamics calculations
Molecular dynamics calculations were performed at 310 K and constant pressure of 1 atm as NVT ensembles using NAMD 2.11 16 and using CHARMM27 force field parameters. 17 The starting coordinates for molecular dynamics were taken from the ectodomain of the GPIIb/IIIa β integrin (PDB ID: 5HDB).
18
The system was solvated using a TIP3 water model 19 with a minimum of 10 Å padding in all directions, neutralized for charges, and the ion concentration adjusted to 150 mM NaCl using VMD. 20 Bond lengths involving hydrogen atoms were constrained using the SHAKE algorithm as implemented in NAMD. Periodic boundary conditions were used and electrostatic potentials evaluated every 4 fs using a particle mesh Ewald summation (grid spacing 1.0 Å). Short-range nonbonded interactions were evaluated every 2 fs. The initial structure was energy minimized by applying 1000 steps of conjugate gradient minimization. Both wild-type and mutant (GPIIIa Asp458Gly) proteins were equilibrated for 5 ns simulation time before the production run. Temperature of the system was controlled by a Langevin thermostat with a temperature coupling constant of 1. A cutoff for exclusion of long-range interactions of 16 Å and 9 Å was applied for equilibration and production runs, respectively. A switching function for zeroing of the nonbonded potentials was used at 12 Å (equilibration) and 7.5 Å (production run). Production run molecular dynamics was calculated for 100 ns simulation time. Analysis of the MD trajectories was performed using VMD 20 including the salt bridge plug-in (V1.1) embedded in VMD.
RESULTS
Serology
Initial screening with a panel of platelets from blood group O donors typed for HPA-1a/b, -2a/b, -3a/b, -4a/b, 5a/b, and 15a/b using both the PIFT and MAIPA assay failed to detect platelet reactive antibodies. Incubation of paternal platelets with maternal serum (Anti-Bl(a)) revealed IgG antibodies in the PIFT assay (MCF = 11.000; mean + 3SD = 1.057). Strongly reactive IgG antibodies were also detected in the GPIIb/IIIa and HLA class I MAIPA assays with Anti-Bl(a) D + 1, Bl(a) D + 2 and Bl(a) D + 90 serum samples. The mother was blood group O, the father was A1, and the infant group O, so there was a possibility that anti-A blood group specific IgG antibodies were responsible for the reactions observed in vitro; however, absorption of maternal serum with group A1 red cells effectively removed anti-A without affecting reactivity in the MAIPA assay (Fig. 1 ).
ITGB3 and ITGA2B coding sequence analysis
Maternal DNA and paternal DNA were sequenced to determine if there was an unknown polymorphism that could explain the positive MAIPA crossmatch result. The maternal DNA nucleotide sequence for both ITGB3 and ITGA2B revealed an absence of novel mutations and was consistent with the HPA typing results obtained by PCR-SSP. Paternal DNA revealed a novel mutation in exon 10 of the ITGB3 gene where a A > G substitution was detected at nucleotide position 1373 predicting an aspartic acid to glycine change at amino acid position 458 (Asp458Gly) of the mature protein (Fig. 2) . DNA from the propositus also possessed the same novel mutation as detected in paternal DNA. The novel nucleotide difference between infant and mother in the ITGB3 gene, c.1373A>G, p.Asp458Gly, was confirmed by next-generation sequencing.
The mutation was confirmed as a low-frequency SNP because none of the 100 volunteer blood donors tested were found to possess the "Bl(a)" mutation. The novel mutation has been deposited in the NCBI clinical variation database (SCV000611127).
Confirmation of maternal sera specificity with recombinant GPIIIa mutated to contain the "Bl(a)" SNP To confirm that the maternal antibodies identified in the crossmatch studies were reactive with epitopes associated with the mutation identified in the father and propositus, GPIIIa containing the mutated sequence detected in the father was coexpressed with wild-type GPIIb in HEK293 cells. IgG antibodies in maternal serum samples obtained on three separate occasions were shown specifically to bind to the mutant "Bl(a)" GPIIIa glycoprotein expressed on the HEK293 cells. The same sera failed to recognize the wildtype (nonmutated) GPIIIa on these cells (Fig. 3C) . The integrity of the expressed GPIIb/IIIa proteins was confirmed by using HPA-specific antisera (Fig. 3A) and monoclonal antibodies against GPIIb, GPIIIa, and the GPIIb/IIIa complex (Fig. 3B) .
Predictions on structural changes as a result of Asp458Gly
The position of the amino acid substitution Asp458Gly is illustrated in Fig. 4 and locates this residue to the hinge region between the hybrid domain and the I-EGF-1/PSI domain. The Asp458Gly mutation is situated adjacent to a disulphide-bonded cysteine (Cys459) with a further two cysteine residues in the next four amino acids downstream (sequence FD/GCDCACQ). The high density of disulphide bonding and the associated constraints on structure suggest that, if the disulphide bonding pattern was not affected by the mutation, this Asp458Gly mutation would have minimal impact on both the structure and function of the glycoprotein (Fig. 5 ). Extensive molecular dynamics calculations for both the wild-type protein and the Asp458Gly variant support this hypothesis and suggest that a far-reaching network of salt bridges may stabilize the I-EGF-1/PSI domain even if the disulphide bonding in this domain could be altered or different to the one observed in the crystallized fragment (Fig. 5) . To investigate this prediction, the disulphide bond adjacent to the Asp458Gly residue (Cys459 to Cys405) was released and both cysteines rendered to their thiol form. In the Asp458 variant of the protein, the relative position of the I-EGF-1/PSI domain was observed to be further restrained by a highly stable salt bridge between Asp458 and Arg117 (occupancy of 93%, average distance between N-O 3.5 AE 0.4 Å in 100 ns trajectory) and an intermittent salt bridge with Lys436 (occupancy 16%, average distance between N-O 7.0 AE 2.3 Å) (Fig. 5C) . If the adjacent disulphide bond was reduced (in silico), the salt bridge formed by Asp458-Lys436 was observed to increase significantly in frequency (occupancy 48%, N-O 5.7 AE 2.3 Å). This may suggest that Asp458 is held efficiently in position by a stable salt bridge formation even with removal of the disulphide bond adjacent to Asp458 (Asp458-Arg117 occupancy 98%, average distance between N-O 3.4 AE 0.2 Å). In the case of the Gly458 variant, Arg117 was seen to adopt a highly flexible conformation exposed to the solvent (not shown). An additional intermittent or low-frequency salt bridge was observed for Asp460-Lys436 (occupied approximately 25%), which decreased significantly when the adjacent disulphide bond constraints were removed (thiol form has zero occupancy for this salt bridge). In stark contrast, in the Asp458Gly substituted molecule, this salt bridge was predicted to become a major stabilizing factor (occupancies of 57% and 80% for the disulphide-linked and thiol forms, respectively; Fig. 5C ).
DISCUSSION
This report describes a further example of NAIT due the placental transfer of maternal antibodies against a lowfrequency platelet polymorphism on GPIIb/IIIa inherited by the infant from the father. Sequencing of the coding region of the ITGB3 gene revealed a previously undescribed polymorphism predicting an Asp458Gly substitution in GPIIIa. This mutation was detected in both DNA from the father and the propositus. Located within the exon 10 coding region, the Asp458Gly (nt1373) polymorphism is a change from an acidic amino acid to an aliphatic amino acid mutation in the epidermal growth factor (EGF) 1 domain and between HPA-7w (aa407; nt1297, exon 10) in the hybrid domain and HPA-6w (aa489, nt1544, exon 10) at the boundary between EGF1 and EGF2 domains. The serologic and sequencing data suggested that the SNP designated "Bl(a)" creates an immunogenic epitope capable of inducing alloantibodies, confirmed with the specific reaction of the maternal serum with mutated recombinant (Asp458Gly) GPIIIa and the lack of reactivity with the wild-type GPIIIa glycoprotein (Fig. 3B) . Confirmatory testing was performed by two reference laboratories in both the Netherlands (Sanquin) and Germany (Giessen). The results were consistent with those presented in this article.
The degree of disulphide bonding is relatively high in the I-EGF-1/PSI domain, but controversially, the bonding pattern in this domain has not been reported consistently. The crystal structure analysis with recombinant protein covering a soluble fragment suggests that Cys459 is bonded to Cys432. 18 In contrast, using purified proteolytic fragments derived from human platelets that had been disulphide bonded in vivo (native pattern), Calvete and coworkers assigned the disulphide bonding of Cys459 to Cys463 and Cys432 to Cys681. 21 This apparent discrepancy may be explained by the fact that Cys681 was not expressed in the truncated recombinant protein giving rise to the protein crystals and therefore necessarily providing a different disulphide bonding pattern. An alternative explanation is offered in a report by Zhu and coworkers 22 who provided evidence that the PSI domain contains intrinsic protein-disulphide isomerase activity that may give rise to an alternative disulphide bonding pattern in highly concentrated crystallization solutions. We hypothesized that the presence of a disulphide bond adjacent to the polymorphic site would likely suppress any flexibility in the polypeptide backbone that a substitution by glycine may convey and undertook extensive molecular dynamics calculations to provide a potential explanation. The data suggest that even if the disulphide bonding at Cys459 is different in the native protein from the one observed in the crystallized ectodomain fragment, as might be conceivable in light of an intrinsic proteindisulphide isomerase activity within this domain, 21 a redundancy in the ability to form high-frequency salt bridges could stabilize the orientation of the domain relative to the headpiece of GPIIb/GPIIIa and therefore have important consequences in influencing activation of the integrin through the I-EGF-1/PSI domain. Disulphide-bond exchange dependent as well as independent activation of GPIIb/GPIIIa was reported for this domain. 23, 24 The number of low-frequency HPA polymorphisms has increased as gene sequencing has become more widely available and the importance of crossmatching in apparently antibody-negative clinically diagnosed NAIT cases has become more established. The presence of a low-frequency polymorphism does not automatically mean that antibodies will be formed, 11 but it does increase the suspicion of NAIT and should prompt further investigation. As discussed previously, 5 platelet immunology laboratories must not only be able to detect and identify the antibodies/antigens commonly implicated in NAIT but also have access, either directly or indirectly, to additional resources to investigate the presence of antibodies against low-frequency antigens in cases where there is an overwhelming suspicion of NAIT. A further consequence of elucidating these naturally occurring mutations of GPIIb/IIIa is that, with the aid of molecular dynamics experiments, they provide useful insights into the intra-and intermolecular interactions at play within a protein that is central to hemostasis.
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